Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease

The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease

“…32 In addition, to reduce cardiovascular complications in patients with PAD, 33 there is evidence that statins may also specifically limit PAD progression 34 and improve pain-free walk-ing distance. 35 In our study, lipid-lowering agent use increased from 22% to 66% at follow-up, and this may contribute to the decrease in prevalence of hyperlipidemia.…”

Sex Differences in Peripheral Artery Disease

“…Lipid-lowering therapies (LLT) have revolutionized the primary and secondary prevention of CVD, including PAD. LLT has been shown to reduce MACE and limb events, as well as improve function, in patients with PAD, 156–163 Furthermore, a relationship between lower LDL-C levels and lower risk of limb events has been demonstrated, 164 suggesting that specifying lipid targets may be important to reduce adverse outcomes in patients with PAD.…”

Naftidrofuryl dans l’artériopathie oblitérante des membres inférieurs : une revue systématique de la littérature

“…La simvastatine, autre thérapeutique recommandée dans l'AOMI, permet d'augmenter significativement à six mois la distance de marche sans douleur ainsi que la distance maximale de marche, comparativement à un placebo, de 90 mètres (IC95% [46 -116]) et de 126 mètres (IC95% [101 -151]), respectivement [38]. Ici encore, les résultats sont comparables à ceux du naftidrofuryl.…”